Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00253526
First received: November 11, 2005
Last updated: December 4, 2006
Last verified: December 2006
  Purpose

RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells an help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of pancreatic cancer by blocking blood flow to the tumor. Giving gemcitabine hydrochloride together with bevacizumab after surgery may kill any remaining tumor cells.

PURPOSE: This phase II trial is studying gemcitabine hydrochloride and bevacizumab to see how well they work compared to gemcitabine hydrochloride alone in treating patients who are undergoing surgery for pancreatic cancer.


Condition Intervention Phase
Adenocarcinoma of the Pancreas
Recurrent Pancreatic Cancer
Stage I Pancreatic Cancer
Stage II Pancreatic Cancer
Stage III Pancreatic Cancer
Drug: bevacizumab
Drug: gemcitabine hydrochloride
Procedure: adjuvant therapy
Procedure: anti-cytokine therapy
Procedure: antiangiogenesis therapy
Procedure: antibody therapy
Procedure: biological therapy
Procedure: chemotherapy
Procedure: conventional surgery
Procedure: growth factor antagonist therapy
Procedure: monoclonal antibody therapy
Procedure: surgery
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Phase II Randomized Study of Surgical Resection and Adjuvant Gemcitabine Hydrochloride With Versus Without Bevacizumab in Patients With Adenocarcinoma of the Pancreas

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Detailed Description:

OBJECTIVES:

Primary

  • Compare the disease-free interval in patients with adenocarcinoma of the pancreas treated with surgical resection followed by adjuvant gemcitabine hydrochloride with vs without bevacizumab.

Secondary

  • Compare overall survival in patients treated with these regimens.
  • Evaluate tumor gene expression profiles and levels of tumor angiogenesis markers to establish prognostic indicators for response in patients treated with these regimens.

OUTLINE: This is a randomized, controlled study.

All patients undergo surgical resection for the pancreatic tumor. Within 4-8 weeks after surgery, patients are stratified according to projected 2-year survival (≤ 5% vs > 5% and ≤ 33% vs > 33%). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive gemcitabine hydrochloride IV over 100 minutes on days 1, 8, and 15, and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses. Patients then receive bevacizumab IV alone every 2 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
  • Arm II: Patients receive gemcitabine hydrochloride IV over 100 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically.

PROJECTED ACCRUAL: A total of 130 patients will be accrued for this study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically or cytologically confirmed adenocarcinoma of the pancreas
  • No evidence of distant metastasis on laparoscopy
  • No superior mesenteric artery or thrombosed superior mesenteric vein involvement
  • Superior mesenteric vein or portal vein involvement allowed
  • Evidence of a pancreatic mass by radiographic or endoscopic examination

PATIENT CHARACTERISTICS:

Performance status

  • ECOG 0-1

Life expectancy

  • Not specified

Hematopoietic

  • WBC ≥ 2,500/mm^3
  • Absolute neutrophil count ≥ 1,250/mm^3
  • Platelet count ≥ 100,000/mm^3

Hepatic

  • Hepatitis B surface antigen negative
  • Hepatitis C virus negative
  • No history of hepatic cirrhosis

Renal

  • Creatinine ≤ 2.0 mg/dL
  • Proteinuria negative or trace by urinalysis OR
  • Protein < 1 g on 24 hr urine collection
  • No active gross hematuria

Cardiovascular

  • No severe congestive heart failure
  • No active ischemic heart disease
  • No ischemic changes on a cardiac thallium stress test
  • No uncontrolled hypertension (i.e., blood pressure ≤ 150/100 mm Hg despite antihypertensive therapy)
  • No active coagulation disorder

Pulmonary

  • No active gross hemoptysis

Other

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during the adjuvant therapy part of trial
  • HIV negative
  • No active infection
  • No wound healing problem from recent invasive procedure
  • No significant history of medical illness that would preclude patient from undergoing an operative procedure
  • No other malignancy requiring systemic therapy

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • Recovered from prior immunotherapy for pancreatic cancer
  • No prior bevacizumab

Chemotherapy

  • Recovered from prior chemotherapy for pancreatic cancer
  • No prior gemcitabine hydrochloride

Endocrine therapy

  • Recovered from prior hormonal therapy for pancreatic cancer

Radiotherapy

  • Recovered from prior radiotherapy for pancreatic cancer
  • No prior radiotherapy to the pancreas

Surgery

  • No prior definitive resection of the primary pancreatic tumor
  • Prior surgery, other than resection of the primary tumor, allowed

Other

  • More than 3 weeks since prior systemic therapy for this cancer
  • No concurrent therapeutic anticoagulation causing elevated PT or PTT
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00253526

Sponsors and Collaborators
Investigators
Principal Investigator: Richard E. Royal, MD, FACS National Cancer Institute (NCI)
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00253526     History of Changes
Obsolete Identifiers: NCT00158392
Other Study ID Numbers: CDR0000448825, NCI-05-C-0158, NCI-P6503
Study First Received: November 11, 2005
Last Updated: December 4, 2006
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Adenocarcinoma
Pancreatic Neoplasms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Antibodies
Immunoglobulins
Antibodies, Monoclonal
Gemcitabine
Mitogens
Bevacizumab
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antimetabolites
Antineoplastic Agents
Therapeutic Uses
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors

ClinicalTrials.gov processed this record on April 23, 2014